Humana's Star Ratings recovery is emerging as a key catalyst for its Medicare Advantage turnaround, with the company targeting a return to top-quartile performance by bonus year 2028. The company defines top-quartile performance as Stars revenue per member per month 10% above the peer median, and a successful recovery could improve the economics of its MA plans and complement other margin initiatives. Early execution signals are encouraging, with the rate of improvement across 11 of 12 selected HEDIS and patient-safety measures outpacing historical trends. The October Centers for Medicare & Medicaid Services Stars release will be the key near-term test, and a meaningful rebound could strengthen the case that Humana is on a credible path toward its 2028 margin target of at least 3% pretax. Shares of Humana have gained 47.6% year to date, outperforming the broader industry's 20.2% growth, and the stock trades at a forward price-to-earnings ratio of 29.24X versus the industry average of 15.98X.
Humana IncStar Ratings recovery is a key catalyst for MA turnaround, targeting top-quartile performance and margin target
UnitedHealth Group Incorporated
Elevance Health Inc